Cytoprotection of PEG-modified adult porcine pancreatic islets for improved xenotransplantation

Biomaterials

Volumn 26, Issue 4, 2005, Pages 403-412

  Xie, Dong ^a   Smyth, Cheryl A ^b   Eckstein, Christopher ^b   Bilbao, Guadalupe ^b   Mays, Jimmy ^c   Eckhoff, Devin E ^b   Contreras, Juan L ^b  

^a and Radiation Oncology   (United States)

^b Kentucky   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Antibody complement mediated cytotoxicity; Cell viability; Characterization; Cytoprotection; In vitron and in vivo islet functionality; PEG derivatives; Synthesis; Xenotransplantation

Indexed keywords

BIOTECHNOLOGY; INSULIN; METABOLISM; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; TRANSPLANTATION (SURGICAL);

CYTOTOXICITY; HUMAN SERUM;

BIOMATERIALS;

ALBUMIN; ANTIBODY; COMPLEMENT; GLUCOSE; INSULIN; LACTATE DEHYDROGENASE; MACROGOL; STREPTOZOCIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CELL CULTURE; CELL MEMBRANE; CELL PROTECTION; CELL VIABILITY; CHEMICAL MODIFICATION; CHEMICAL REACTION; COMBINED IMMUNODEFICIENCY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DIABETES MELLITUS; ENZYME RELEASE; GLUCOSE BLOOD LEVEL; IMMUNE DEFICIENCY; INCUBATION TIME; INSULIN RELEASE; MALE; METABOLISM; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PURIFICATION; SERUM; SURFACE PROPERTY; SYNTHESIS; XENOTRANSPLANTATION;

ANIMALS; BIOCOMPATIBLE MATERIALS; BLOOD GLUCOSE; CATTLE; CELLS, CULTURED; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MATERIALS TESTING; MICE; MICE, SCID; PANCREAS, ARTIFICIAL; POLYETHYLENE GLYCOLS; TISSUE ENGINEERING; TRANSPLANTATION, HETEROLOGOUS;

SUIDAE;

EID: 3242732200     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2004.02.048     Document Type: Article

References (40)

1. Bennet W., Sundberg B., Groth C-.G., Brendel M.D., Brandhorst D., Brandhorst H., Bretzel R.G., Elgue G., Larsson R., Nilsson B., Korsgren O. Incompatibility between human blood and isolated islets of Langerhans. Diabetes. 48:1999;1907-1914
2. Oiknine R., Mooradian A.D. Drug therapy of diabetes in the elderly. Biomed Pharmacother. 57:2003;231-239
3. Kelly W.D., Lillehei R.C., Merkel F.K., Idezuki Y., Goetz F.C. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 61:1967;827-837
4. Chen J-.P., Chu I-.M., Shiao M-.Y., Hsu B.R-.S., Fu S.H. Microencapsulation of islets in PEG-amine modified alginate-poly(L-lysine)- alginate microcapsules for constructing bioartificial pancreas. J Ferment Bioeng. 86:1998;185-190
5. Irgang M., Sauer I.M., Karlas A., Zeilinger K., Gerlach J.C., Kurth R., Neuhaus P., Denner J. Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J Clinal Virol. 28:2003;141-154
6. Heneine W., Tibell A., Switzer W.M., Sandstrom P., Rosales G.V., Mathews A., Korsgren O., Chapman L.E., Folks T.M., Groth C.G. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet. 352:1998;695-699
7. Trivedi N., Keegan M., Steil G.M., Hollister-Lock J., Hasenkamp W.M., Colton C.K., Bonner-Weir S., Weir G.C. Islets in alginate macrobeads reverse diabetes despite minimal acute insulin secretory responses. Transplantation. 71(2):2001;203-211
8. Rýhova B. Immunocompatibility and biocompatibility of cell delivery systems. Adv Drug Deliv Rev. 42:2000;65-80
9. Chang T.M.S. Artificial cells with emphasis on bioencapsulation in biotechnology. Biotechnol Annu Rev. 1:1995;267-295
10. Chandy T., Mooradian D.L., Rao G.H.R. Evaluation of modified alginate-chitosan-polyethylene glycol microcapsules for cell encapsulation. Artif Organs. 23(10):1999;894-903
11. Young T-.H., Chuang W-.Y., Hsieh M-.Y., Chen L-.W., Hsu J-.P. Assessment and modeling of poly(vinyl alcohol) bioartificial pancreas in vivo. Biomaterials. 23:2002;3495-3501
12. Burczak K., Gamian E., Kochman A. Long-term in vivo performance and biocompatibility of poly(vinyl alcohol) hydrogel macrocapsules for hybrid-type artificial pancreas. Biomaterials. 17:1996;2351-2356
13. Abalovich A., Jatimliansky C., Diegex E., Arias M., Altamirano A., Amorena C., Martinez B., Nacucchio M. Pancreatic islets microencapsulation with polylactide-co-glycolide. Transplant Proc. 33:2001;1977-1979
14. Sefton M.V., Broughton R.L., Sugamori M.E., Mallabone C.L. Hydrophilic polyacrylates for the microencapsulation of fibroblasts or pancreatic islets. J Controlled Release. 6:1987;177-187
15. de Vos P., van Hoogmoed C.G., van Zanten J., Netter S., Strubbe J.H., Busscher H.J. Long-term biocompatibility, chemistry, and function of microencapsulated pancreatic islets. Biomaterials. 24:2003;305-312
16. Soon-Shiong P. Treatment of type I diabetes using encapsulated islets. Adv Drug Deliv Rev. 35:1999;259-270
17. Korbutt G.S., Elliott J.F., Ao Z., Flashner M., Warnock G.L., Rajotte R.V. Microencapsulation of neonatal porcine islets: long-term reversal of diabetes in nude mice and in vitro protection from human complement mediated cytolysis. Transplant Proc. 29:1997;2128
18. de Vos P., De Haan B., Schilfgaarde R. Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules. Biomaterials. 18:1997;273-278
19. Korbutt G.S., Elliott J.F., Ao Z., Flashner M., Warnock G.L., Rajotte R.V. Microencapsulation of neonatal porcine islets: long-term reversal of diabetes in nude mice and in vitro protection from human complement mediated cytolysis. Cell Transplant. 5:1996;55
20. Kobayashi T., Aomatsu Y., Kanehiro H., Hisanaga M., Nakajima Y. Protection of NOD islet isograft from autoimmune destruction by agarose microencapsulation. Transplant Proc. 35:2003;484-485
21. Aomatsu Y., Nakajima Y., Ohyama T., Kin T., Kanehiro H., Hisanaga M., Ko S., Nagao M., Tatekawa Y., Sho M. Efficacy of agarose/polystyrene sulfonic acid microencapsulation for islet xenotransplantation. Transplant Proc. 32:2000;1071-1072
22. Lanza R.P., Kuhtreiber W.M., Ecker D., Staruk J.E., Chick W.L. Xenotransplantation of porcine and bovine islets without immunosuppression using uncoated alginate microspheres. Transplantation. 59:1995;1377-1384
23. Jeong S.T., Byun S.M. Decreased agglutinability of methoxy-polyethylene glycol attached red blood cells: significance as blood substitute. Artif Cells Blood Subs Immob Biotechnol. 24(5):1996;503-511
24. Murad K.L., Mahany K.L., Brugnara C., Kuypers F.A., Eaton J.W., Scott M.D. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly(ethylene glycol). Blood. 93(6):1999;2121-2127
25. Murad K.L., Gosselin E.J., Eaton J.W., Scott M.D. Stealth cells: prevention of major histocompatibility complex Class II-mediated T-cell activation by cell surface modification. Blood. 94(6):1999;2135-2141
26. Scott M.D., Murad K.L. Cellular camouflage: fooling the immune system with polymers. Curr Pharm Des. 4:1998;423-438
27. Hortin G.T., Lok H.T., Huang S.T. Progress toward preparation of universal donor red cells. Artif Cells Blood Subs Immob Biotechnol. 25(5):1997;487-491
28. Hortin GT, Huang ST. Polyethylene glycol-protein compositions which reduce the antigenic display of red blood cells, US Patent No. 6129912, 2000.
29. Panza J.L., Wagner W.R., Rilo H.L., Rao R.H., Beckman E.J., Russell A.J. Treatment of rat pancreatic islets with reactive PEG. Biomaterials. 21(11):2000;1155-1164
30. Ishihara K. Blood compatible polymers. Tsuruta T., et al. Biomedical applications of polymeric materials. 1993;371 CRC Press, Boca Raton, FL. [Chapter 6]
31. Amiji M, Park K. Surface modification of polymeric biomaterials with poly(ethylene oxide), albumin, and heparin for reduced thrombogenicity. In: Cooper SL, Bamford CH, Tsuruta T, editors. Polymer biomaterials in solution, as interfaces and as solids. Utrecht, The Netherlands: VSP; 1995. p. 535-52.
32. Abuchowski A., van Es T., Palczuk N.C., Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 252(11):1977;3578-3581
33. Abuchowski A., Kazo G.M., Verhoest C.R., van Es T., Kafkewitz D., Nucci M.L., Viau A.T., Davis F.F. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys. 7(2):1984;175-186
34. Kynclova E., Elsner E., Kopf A., Hawa G., Schalkhammer T., Pittner F. Novel method for coupling of poly(ethyleneglycol) to carboxylic acid moieties of proteins. J Mol Recog. 9(5-6):1996;644-651
35. Ricordi C., Finke E.H., Lacy P.E. A method for the mass isolation of islets from the adult pig pancreas. Diabetes. 35(6):1986;649-653
36. Ricordi C., Gray D.W., Hering B.J., Kaufman D.B., Warnock G.L., Kneteman N.M., et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat. 27(3):1990;185-195
37. Contreras J.L., Bilbao G., Smyth C.A., Eckhoff D.E., Xiang X.L., Jenkins S., Cartner S., Curiel D.T., Thomas F.T., Thomas J.M. Gene transfer of the Bcl-2 gene confers cytoprotection to isolated adult porcine pancreatic islets exposed to xenoreactive antibodies and complement. Surgery. 130(2):2001;166-174
38. Weber M., Deng S., Kucher T., Shaked A., Ketchum R.J., Brayman K.L. Adenoviral transfection of isolated pancreatic islets: a study of programmed cell death (apoptosis) and islet function. J Surg Res. 69(1):1997;23-32
39. Janjic D., Wollheim C.B. Islet cell metabolism is reflected by the MTT (tetrazolium) colorimetric assay. Diabetologia. 35:1992;482-485
40. Jo S., Engel P.S., Mikos A.G. Synthesis of poly(ethylene glycol)-tethered poly(propylene fumarate) and its modification with GRGD peptide. Polymer. 41:2000;7595-7604